Cover Image
市場調查報告書

抗發炎治療的全球市場 - 2014∼2020年的市場機會及市場預測

World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020

出版商 Allied Market Research 商品編碼 335354
出版日期 內容資訊 英文 136 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗發炎治療的全球市場 - 2014∼2020年的市場機會及市場預測 World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020
出版日期: 2015年06月01日 內容資訊: 英文 136 Pages
簡介

在自體免疫疾病和呼吸疾病增加,以及更具效果且副作用少的抗炎生物醫藥品的出現等背景下,抗炎症治療全球市場展現出成長之勢,預測2014年到2020年間將以5.9%的年複合成長率(CAGR)持續擴大。

本報告詳查抗發炎治療的全球市場,提供您推動市場成長要素,阻礙因素,市場趨勢,市場機會,各公司的策略等,到目前市場方案分析與2020年前的市場預測。該市場可依各適應症,各類藥物,以及地區別加以分類,本報告基於各分類提供更細分的市場分析與未來預測。同時更提供這個市場上主要企業包含業績,策略,以及最近的企業發展和SWOT分析之詳細企業簡介。

第1章 序論

  • 關於本報告
  • 主要的成果
  • 主要市場領域
  • 調查手法

第2章 摘要整理

  • 企業員工水準的觀點
  • 到2025年前的市場預測方案

第3章 市場概要

  • 市場定義及範圍
  • 重要的調查結果
    • 左右市場的最重要要素
    • 最重要投資領域
    • 為求勝出的最重要策略
  • 政府法規
  • 保險給付方案
  • 波特的五力分析
  • 價值鏈分析
  • 市場佔有率分析 - 2014年
  • 市場動態
    • 推動市場成長要素
      • 自體免疫疾病及呼吸系統疾病的增加
      • 即將完成的新治療藥
      • 抗發炎治療藥的攝取率增加
    • 阻礙市場成長要素
      • 抗發炎治療藥的副作用
      • 專利的到期
    • 市場機會
      • 現有治療藥的生技仿製藥的開發
      • 打入開發中地區的新興市場

第4章 從各適應症來看的抗發炎治療全球市場

  • 各適應症市場規模及未來預測
    • 各地區市場規模及未來預測
    • 類風濕性關節炎
    • 骨關節炎
    • 僵直性脊椎炎
    • 乾癬性關節炎
    • 痛風
  • 呼吸疾病
    • 各地區市場規模及未來預測
    • 氣喘
    • 慢性阻塞性肺病
  • 多發性硬化症
    • 各地區市場規模及未來預測
  • 乾癬
    • 各地區市場規模及未來預測
  • 發炎性腸道疾病
    • 各地區市場規模及未來預測
  • 其他發炎性疾病
    • 各地區市場規模及未來預測

第5章 從各類藥物來看的抗發炎治療全球市場

  • 抗發炎生物醫藥品
    • 重要的市場趨勢
    • 市場成長要素及市場機會
    • 各地區市場規模及未來預測
  • 非類固醇系抗發炎藥 (NSAIDs)
    • 重要的市場趨勢
    • 市場成長要素及市場機會
    • 各地區市場規模及未來預測
  • 皮質類固醇
    • 重要的市場趨勢
    • 市場成長要素及市場機會
    • 各地區市場規模及未來預測
  • 其他抗發炎藥

第6章 從各地區來看抗發炎治療全球市場

  • 北美
    • 重要的市場趨勢
    • 市場成長要素與市場機會
    • 市場規模及未來預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 重要的市場趨勢
    • 市場成長要素與市場機會
    • 市場規模及未來預測
    • 英國
    • 德國
    • 法國
    • 其他歐洲各國
  • 亞太地區
    • 市場成長要素與市場機會
    • 市場規模及未來預測
    • 日本
    • 中國
    • 印度
    • 其他的亞太地區各國
  • 南美,中東,及非洲 (LAMEA) 地區
    • 重要的市場趨勢
    • 市場成長要素與市場機會
    • 市場規模及未來預測
    • 南美
    • 中東及非洲地區

第7章 企業簡介

  • Pfizer Inc.
    • 公司概要
    • 企業簡短的描寫
    • 商務業績
    • 策略性動向和企業發展
    • SWOT分析
  • AbbVie Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Hoffmann-La Roche AG
  • Eli Lily and Company
  • AstraZeneca PLC.
  • Amgen Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world. Symptomatic relief during the inflammation provides relief to the patients suffering from inflammatory autoimmune diseases. Although there are multiple anti-inflammatory drugs approved in the market, there is an indispensable need for better and novel anti-inflammatory therapeutics with lesser side effects and better efficacy.

The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth.

The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period.

Geographically, the market is segmented into four regions namely North America, Europe, Asia-Pacific and LAMEA. Among regions, North America holds the largest share accounting for 45.7% share of the global anti-inflammatory therapeutics market; however, the Asia-Pacific region is expected to exhibit the fastest growth during the forecast period. Major market players have adopted innovative strategies such novel drug development and product launch (novel and indication expansion) to increase their market presence. In 2014, AstraZeneca had five anti-inflammatory drugs in the final stages of drug development. These drugs are lesinurad, sifalimumab, anifrolumab, mavrilimumab and brodalumab. The companies have filed new patents to overcome the issues of patent expiries of their existing drugs, and to gain a prominent market share. The key companies profiled in this report include Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.

KEY MARKET BENEFITS:

  • The report provides a quantitative analysis of the current market and estimations during 2014 - 2020 that assist in identifying the prevailing market opportunities to capitalize.
  • Exhaustive analysis of the global anti-inflammatory therapeutics market by product type helps in understanding the types of therapeutics that are currently being used along with the categories that would gain prominence in the future.
  • Competitive intelligence (of leading manufacturers and distributors of anti-inflammatory therapeutics) helps in understanding the competitive scenario across the geographies.
  • Comprehensive analysis of factors that drive and restrict the growth of the global anti-inflammatory therapeutics market is provided.
  • SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.
  • The Country level analysis of anti-inflammatory therapeutics market conditions has been provided in this report.

KEY MARKET SEGMENTS:

The Global Anti-inflammatory Therapeutics Market is segmented below:

  • Global Anti-inflammatory Therapeutics Market By Indication
    • Arthritis
    • Respiratory diseases
    • Multiple sclerosis
    • Psoriasis
    • Inflammatory bowel disease
    • Other inflammatory diseases
  • Global Anti-inflammatory Therapeutics Market Drug Class
    • Anti-inflammatory Biologics
    • Non-Steroidal Anti-inflammatory drugs (NSAIDs)
    • Corticosteroids
  • Global Anti-inflammatory Therapeutics Market By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • U.K.
      • Germany
      • France
      • Others
    • Asia-Pacific
      • China
      • Japan
      • India
      • Others
    • LAMEA
      • Latina America
      • Middle East and Africa

Table of Contents

CHAPTER: 1 - INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Benefits
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER: 2 - EXECUTIVE SUMMARY

  • 2.1. CXO Perspective
  • 2.2. Market Beyond What to Expect by 2025($million)
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER: 3 - MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
    • 3.2.3. Top winning strategies
  • 3.3. Government Regulation
  • 3.4. Reimbursement Scenario
  • 3.5. Porter's Five Force Analysis
    • 3.5.1. Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
    • 3.5.2. Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
    • 3.5.3. High capital investment and patent provision lowers the threats from new entrants
    • 3.5.4. Difficulty to imitate the original biologics lowers the threat of substitutes
    • 3.5.5. Industry rivalry is low to moderate due to presence of few competitors
  • 3.6. Value Chain Analysis
  • 3.7. Market Share Analysis, 2014
  • 3.8. Market Dynamics
    • 3.8.1. Drivers
      • 3.8.1.1. Rising incidences of autoimmnue and respiratory conditions:
      • 3.8.1.2. New Drugs in Pipeline
      • 3.8.1.3. Increasing adoption rate of anti-inflammatory drugs
    • 3.8.2. Restraints
      • 3.8.2.1. Side effects of anti-inflammtory drugs
      • 3.8.2.2. Patenet expiries
    • 3.8.3. Opportunities
      • 3.8.3.1. Developing biosimilars for the existing drugs
      • 3.8.3.2. Tapping the emerging markets in developing regions

CHAPTER: 4 - GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION

  • 4.1. Market size and forecast by Indication
    • 4.2.1. Market size and forecast by region
    • 4.2.2. Rheumatoid Arthritis
    • 4.2.3. Osteoarthritis
    • 4.2.4. Ankylosing Spondylitis
    • 4.2.5. Psoriatic Arthritis
    • 4.2.6. Gout
  • 4.3. Respiratory Diseases
    • 4.3.1. Market size and forecast by region
    • 4.3.2. Asthma
    • 4.3.3. Chronic obstructive pulmonary disease(COPD)
  • 4.4. Multiple Sclerosis
    • 4.4.1. Market size and forecast by region
  • 4.5. Psoriasis
    • 4.5.1. Market size and forecast by region
  • 4.6. Inflammatory Bowel Disease(IBD)
    • 4.6.1. Market size and forecast by region
    • 4.6.2. Crohn's Disease
    • 4.6.3. Ulcerative Colitis
  • 4.7. Other Inflammatory Diseases
    • 4.7.1. Market size and forecast by region

CHAPTER: 5 - GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS

  • 5.1. Anti-inflammatory Biologics
    • 5.1.1. Key market trend
    • 5.1.2. Market growth factors and opportunities
    • 5.1.3. Market size and forecast by region
  • 5.2. Nonsteroidal Anti-Inflammatory Drugs(NSAIDs)
    • 5.2.1. Key market trend
    • 5.2.2. Market growth factors and opportunities
    • 5.2.3. Market size and forecast by region
  • 5.3. Corticosteroids
    • 5.3.1. Key market trends
    • 5.3.2. Market growth factors and opportunities
    • 5.3.3. Market size and forecast by region
  • 5.4. Other Anti-Inflammatory Drugs

CHAPTER: 6 - GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY

  • 6.1. North America
    • 6.1.1. Key market trends
    • 6.1.2. Key growth factors and opportunities
    • 6.1.3. Market size and forecast
    • 6.1.4. United States
    • 6.1.5. Canada
    • 6.1.6. Mexico
  • 6.2. Europe
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast
    • 6.2.4. United Kingdom
    • 6.2.5. Germany
    • 6.2.6. France
    • 6.2.7. Rest of Europe
  • 6.3. Asia Pacific
    • 6.3.1. Key growth factors and opportunities
    • 6.3.2. Market size and forecast
    • 6.3.3. Japan
    • 6.3.4. China
    • 6.3.5. India
    • 6.3.6. Rest of Asia Pacific
  • 6.4. LAMEA
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast
    • 6.4.4. Latin America
    • 6.4.5. Middle East and Africa

CHAPTER: 7 - COMPANY PROFILES

  • 7.1. Pfizer Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Business performance
    • 7.1.4. Strategic moves and developments
    • 7.1.5. SWOT analysis of Pfizer, Inc.
  • 7.2. AbbVie Inc.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Business performance
    • 7.2.4. Strategic Moves and Developments
    • 7.2.5. SWOT analysis of AbbVie Inc.
  • 7.3. Johnson & Johnson
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Business performance
    • 7.3.4. Strategic moves and developments
    • 7.3.5. SWOT analysis & strategic conclusions
  • 7.4. GlaxoSmithKline plc
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Business performance
    • 7.4.4. Strategic moves and developments
    • 7.4.5. SWOT analysis & strategic conclusions
  • 7.5. Merck & Co., Inc.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Business performance
    • 7.5.4. Strategic moves and developments
    • 7.5.5. SWOT analysis and strategic conclusions
  • 7.6. Novartis AG
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Business Performance
    • 7.6.4. Strategic moves and developments
    • 7.6.5. SWOT analysis and strategic conclusions
  • 7.7. F. Hoffmann-La Roche AG
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Business performance
    • 7.7.4. Strategic moves and developments
    • 7.7.5. SWOT analysis and strategic conclusions
  • 7.8. Eli Lily and Company
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Business performance
    • 7.8.4. Strategic moves and developments
    • 7.8.5. SWOT analysis and strategic conclusions
  • 7.9. AstraZeneca PLC.
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Business performance
    • 7.9.4. Strategic moves and developments
    • 7.9.5. SWOT analysis and strategic conclusions
  • 7.10. Amgen Inc.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Business performance
    • 7.10.4. Strategic moves and developments
    • 7.10.5. SWOT analysis and strategic conclusions

List of Tables

  • TABLE 1: GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET MODERATE GROWTH SCENARIO, REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
  • TABLE 2: GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET RAPID GROWTH SCENARIO REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
  • TABLE 3: GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET DIMINISHING GROWTH SCENARIO REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
  • TABLE 4: PATENT EXPIRY OF MAJOR BRANDS
  • TABLE 5: PROJECTED INCIDENCE OF ARTHRITIS IN U.S
  • TABLE 6: GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
  • TABLE 7: GLOBAL ARTHRITIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
  • TABLE 8: GLOBAL RESPIRATORY DISEASES ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
  • TABLE 9: GLOBAL MULTIPLE SCLEROSIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
  • TABLE 10: GLOBAL PSORIASIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
  • TABLE 11: GLOBAL INFLAMMTORY BOWEL DISEASE ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
  • TABLE 12: GLOBAL OTHER INFLAMMTORY DISEASES ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
  • TABLE 13: GLOBAL ANTI INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020, $MILLION
  • TABLE 14: GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
  • TABLE 15: GLOBAL ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 16: GLOBAL NSAIDS THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 17: GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
  • TABLE 18: GLOBAL CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 19: GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 20: NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
  • TABLE 21: NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
  • TABLE 22: EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
  • TABLE 23: EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
  • TABLE 24: ASIA PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
  • TABLE 25: ASIA PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
  • TABLE 26: LAMEA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
  • TABLE 27: LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
  • TABLE 28: PFIZER INC SNAPSHOT
  • TABLE 29: ABBVIE INC. SNAPSHOT
  • TABLE 30: JOHNSON & JOHNSON SNAPSHOT
  • TABLE 31: GLAXOSMITHKLINE SNAPSHOT
  • TABLE 32: MERCK & CO SNAPSHOT
  • TABLE 33: NOVARTIS AG SNAPSHOT
  • TABLE 34: F. HOFFMANN-LA ROCHE AG SNAPSHOT
  • TABLE 35: ELI LILLY SNAPSHOT
  • TABLE 36: ASTRAZENECA SNAPSHOT
  • TABLE 37: AMGEN INC SNAPSHOT

List of Figures

  • FIG. 1: TOP IMPACTING FACTORS, MODERATE GROWTH SCENARIO (2020-2025)
  • FIG. 2: TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2020-2025)
  • FIG. 3: TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2020-2025)
  • FIG. 4: TYPES OF ANTI-INFALMMATORY THERAPEUTICS:
  • FIG. 5: TOP FACTORS IMPACTING ON GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
  • FIG. 6: TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
  • FIG. 7: TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICSMARKET
  • FIG. 8: PHARMACEUTICALS REGULATORY PATHWAY (U.S.)
  • FIG. 9: PORTER'S FIVE FORCES ANALYSIS
  • FIG. 10: VALUE CHAIN OF GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET
  • FIG. 11: MARKET SHARE ANALYSIS, 2014
  • FIG. 12: FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
  • FIG. 13: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 14: FINANCIAL REVENUES BY YEAR ($MILLION)
  • FIG. 15: SWOT ANALYSIS & STRATEGIC CONCLUSIONS
  • FIG. 16: ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
  • FIG. 17: FINANCIAL REVENUES OF HUMIRA ($MILLION)
  • FIG. 18: SWOT ANALYSIS & STRATEGIC CONCLUSIONS
  • FIG. 19: PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
  • FIG. 20: SWOT ANALYSIS & STRATEGIC CONCLUSIONS
  • FIG. 21: GLAXOSMITHKLINE'S FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 22: FINANCIAL REVENUES BY THERAPY AREA
  • FIG. 23: SWOT ANALYSIS & STRATEGIC CONCLUSIONS
  • FIG. 24: FINANCIAL REVENUES BY YEAR ($MILLION)
  • FIG. 25: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 26: SWOT ANALYSIS & STRATEGIC CONCLUSIONS
  • FIG. 27: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 28: FINANCIAL REVENUES BY SEGMENT (2014)
  • FIG. 29: SWOT ANALYSIS & STRATEGIC CONCLUSIONS
  • FIG. 30: FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
  • FIG. 31: FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
  • FIG. 32: SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
  • FIG. 33: FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
  • FIG. 34: SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
  • FIG. 35: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 36: FINANCIAL REVENUES BY YEAR ($MILLION)
  • FIG. 37: SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
  • FIG. 38: FINANCIAL REVENUES BY PRODUCT (2014)
  • FIG. 39: FINANCIAL REVENUES BY YEAR ($MILLION)
  • FIG. 40: SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
Back to Top